Aclaris Therapeutics (ACRS) Long-Term Investments (2014 - 2026)

Aclaris Therapeutics' Long-Term Investments history runs 10 years deep, the most recent figure standing at $85.4 million for Q1 2026.

• In Q1 2026, Long-Term Investments changed 0.19% year-over-year to $85.4 million; the TTM figure through Mar 2026 stood at $85.4 million (changed 0.19% YoY), while the FY2025 annual figure was $60.6 million, down 32.88% from the prior year.
• Long-Term Investments for Q1 2026 stood at $85.4 million, up from $60.6 million in the prior quarter.
• The five-year high for Long-Term Investments was $91.0 million in Q2 2023, with the low at $7.2 million in Q2 2022.
• The 5-year median for Long-Term Investments is $61.7 million (2023), against an average of $56.6 million.
• The sharpest annual moves came in 2022 and 2023: Long-Term Investments slumped 79.07% in 2022, then soared 1160.1% in 2023.
• Aclaris Therapeutics' Long-Term Investments stood at $12.2 million in 2022, then surged by 412.75% to $62.8 million in 2023, then surged by 43.86% to $90.3 million in 2024, then sank by 32.88% to $60.6 million in 2025, then surged by 40.85% to $85.4 million in 2026.
• Business Quant data shows ACRS's Long-Term Investments at $85.4 million in Q1 2026, $60.6 million in Q4 2025, and $71.3 million in Q3 2025.